Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial

Rosner, 1980, Noninvasive breast carcinoma: results of a national survey by the American College of Surgeons, Ann Surg, 192, 139, 10.1097/00000658-198008000-00001 Lagios, 1982, Duct carcinoma in situ: relationship of extent of noninvasive disease to the frequency of occult invasion, multicentricity, lymph node metastases, and short-term treatment failures, Cancer, 50, 1309, 10.1002/1097-0142(19821001)50:7<1309::AID-CNCR2820500716>3.0.CO;2-# Ernster, 1996, Incidence of and treatment for ductal carcinoma in situ of the breast, JAMA, 275, 913, 10.1001/jama.1996.03530360023033 Fisher, 1985, Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer, N Eng J Med, 312, 665, 10.1056/NEJM198503143121101 Fisher, 1993, Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer, N Engl J Med, 328, 1581, 10.1056/NEJM199306033282201 Fisher, 1998, Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17, J Clin Oncol, 16, 441, 10.1200/JCO.1998.16.2.441 Jordan, 1976, Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata, Eur J Cancer, 12, 419, 10.1016/0014-2964(76)90030-X Jordan, 1980, Evaluation of the antitumour activity of the nonsteroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model, Eur J Cancer, 16, 239, 10.1016/0014-2964(80)90156-5 Fisher, 1989, A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors, N Eng J Med, 320, 479, 10.1056/NEJM198902233200802 Fisher, 1991, New perspective on cancer of the contralateral breast: a marker for assessing tamoxifen as a preventive agent, J Natl Cancer Inst, 83, 1278, 10.1093/jnci/83.18.1278 Fisher, 1998, Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study, J Natl Cancer Inst, 90, 1371, 10.1093/jnci/90.18.1371 Fisher, 1985, Lumpectomy and axillary dissection for breast cancer: surgical, pathological, and radiation considerations, World J Surg, 9, 692, 10.1007/BF01655182 Prentice, 1978, The analysis of failure times in the presence of competing risks, Biometrics, 34, 541, 10.2307/2530374 Gaynor, 1993, On the use of cause-specific failure and conditional failure probabilities: examples from clinical oncology data, J Am Stat Assoc, 88, 400, 10.1080/01621459.1993.10476289 Fleming, 1984, Designs for group sequential tests, Controlled Clin Trials, 5, 348, 10.1016/S0197-2456(84)80014-8 Fisher, 1995, Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) Protocol B-17: intraductal carcinoma (duct carcinoma in situ), Cancer, 115, 1310, 10.1002/1097-0142(19950315)75:6<1310::AID-CNCR2820750613>3.0.CO;2-G Fisher, 1997, Pathobiological considerations relating to the treatment of intraductal carcinoma (ductal carcinoma in situ) of the breast, CA Cancer J Clin, 47, 52, 10.3322/canjclin.47.1.52 Fisher ER, Dignam J, Tan Chiu E, et al. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of protocol B-17. Cancer 1999 (in press). Giri, 1989, Oestrogen receptors in benign epithelial lesions and intraductal carcinomas of the breast: an immunohistological study, Histopathology, 15, 575, 10.1111/j.1365-2559.1989.tb01623.x Barnes, 1990, Potential value of hormone receptor assay in carcinoma in situ of breast, Am J Clin Pathol, 94, 533, 10.1093/ajcp/94.5.533 Zafrani, 1994, Mammographically detected ductal in situ carcinoma of the breast analyzed with a new classification: a study of 127 cases: correlation with estrogen and progesterone receptors, P53 and c-erb B-2 proteins, and proliferative activity, Semin Diagn Pathol, 11, 208 Allred, 1997, Biologic and genetic features of in-situ breast cancer, 37 Pallis, 1992, Receptors for estrogen and progesterone in breast carcinoma in situ, Anticancer Res, 12, 2113 Berardo, 1996, Histological grading of noninvasive breast cancer and its relationship to biological features, Lab Invest, 74, 15A Leal, 1995, Ductal carcinoma in situ of the breast: histologic categorization and its relationship to ploidy and immunohistochemical expression of hormone receptors, p53, and c-erb B-2 protein, Cancer, 75, 2123, 10.1002/1097-0142(19950415)75:8<2123::AID-CNCR2820750815>3.0.CO;2-V Recht, 1998, The Fourth EORTC DCIS Consensus Meeting (Château Marquette, Heemskerk, The Netherlands, 23–24 January 1998) Conference Report, Eur J Cancer, 34, 1664, 10.1016/S0959-8049(98)00220-2